J. Marcello

发表

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

John Sampson, Allan H Friedman, A. Friedman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poor documentation prevents adequate assessment of quality metrics in colorectal cancer.

Amy P Abernethy, Meenal Patwardhan, A. Abernethy, 2009, Journal of oncology practice.

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

R. McLendon, A. Friedman, D. Bigner, 2010, Journal of Neuro-Oncology.

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

R. McLendon, A. Friedman, D. Bigner, 2009, British Journal of Cancer.

Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems

A. Abernethy, S. Grambow, M. Patwardhan, 2008, BMC Cancer.

Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.

A. Abernethy, M. Morse, J. Herndon, 2009, Journal of oncology practice.

Comparative Analysis of Yeast Expression Profiles Using an Annotated Microarray Database

Nitin Sawhney, J. Marcello, Kelley C. Larson, 2003 .

The impact of a physician and patient intervention program on dietary intake

P. Lin, L. Svetkey, G. Samsa, 2014 .

The influence of a physician and patient intervention program on dietary intake.

Bryan C. Batch, P. Lin, L. Svetkey, 2013, Journal of the Academy of Nutrition and Dietetics.

Association between Glioma and History of Allergies, Asthma, and Eczema: A Case-Control Study with Three Groups of Controls

D. Bigner, F. Ali-Osman, F. Davis, 2009, Cancer Epidemiology Biomarkers & Prevention.

Association between body mass index and mortality in patients with glioblastoma mutliforme

E. Lipp, L. Jones, F. Ali-Osman, 2010, Cancer Causes & Control.

Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients

D. Barboriak, H. Friedman, D. Reardon, 2008 .

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

R. McLendon, A. Friedman, H. Friedman, 2011, Journal of Neuro-Oncology.

Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

A. Nadeem, H. Wanebo, N. Ready, 2012, American journal of clinical oncology.

Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents

J. Marcello, A. Ohagen, J. Chapman, 2006, Transfusion.

Total dietary antioxidant index and survival in patients with glioblastoma multiforme

M. Wrensch, T. Rice, L. McCoy, 2009, Cancer Causes & Control.

Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas

H. Friedman, D. Reardon, J. Rich, 2008 .

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

A. Friedman, D. Bigner, H. Friedman, 2011, Clinical Cancer Research.

Bevacizumab and daily temozolomide for recurrent glioblastoma

H. Friedman, D. Reardon, A. Desjardins, 2012, Cancer.

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

R. McLendon, H. Friedman, D. Reardon, 2010, Neuro-oncology.

Retinoic Acid Inhibition of Chromatin Remodeling at the Human Immunodeficiency Virus Type 1 Promoter

J. Marcello, G. Viglianti, T. Hanley, 2004, Journal of Biological Chemistry.

Retinoid-Dependent Restriction of Human Immunodeficiency Virus Type 1 Replication in Monocytes/Macrophages

A. Schnitzler, J. Marcello, G. Viglianti, 2004, Journal of Virology.

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

A. Friedman, D. Bigner, J. Herndon, 2008, Clinical Cancer Research.

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Yiting Cao, Mark W Dewhirst, M. Dewhirst, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Effect of Metastatic Site and Decade of Diagnosis on the Individual Burden of Metastatic Melanoma: Contemporary Estimates of Average Years of Life Lost

Amy P Abernethy, A. Abernethy, D. Tyler, 2012, Cancer investigation.

Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy

A. Abernethy, D. Tyler, A. Salama, 2013, PloS one.

Evaluation of 39 cases of pediatric cutaneous head and neck melanoma.

A. Abernethy, K. Nelson, J. Marcello, 2011, Journal of the American Academy of Dermatology.

Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110

J. Marcello, A. Ohagen, J. Chapman, 2004, Vox sanguinis.

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

A. Friedman, H. Friedman, D. Reardon, 2012, International journal of radiation oncology, biology, physics.

Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial

A. Abernethy, J. Tulsky, P. Frith, 2010, The Lancet.

Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial

A. Abernethy, J. Tulsky, P. Frith, 2010, The Lancet.

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

R. McLendon, H. Friedman, D. Reardon, 2009, Journal of Neuro-Oncology.

Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.

R. McLendon, H. Friedman, D. Reardon, 2010 .

Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).

H. Friedman, D. Reardon, J. Kirkpatrick, 2010 .

Bevacizumab and daily temozolomide for recurrent glioblastoma

H. Friedman, D. Reardon, A. Desjardins, 2012, Cancer.

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

R. McLendon, D. Bigner, H. Friedman, 2009, British Journal of Cancer.